| Guidelines for the use and interpretation of assays for monitoring autophagy DJ Klionsky, FC Abdalla, H Abeliovich, RT Abraham, A Acevedo-Arozena, ... Autophagy 8 (4), 445-544, 2012 | 13206* | 2012 |
| Plasma cells require autophagy for sustainable immunoglobulin production N Pengo, M Scolari, L Oliva, E Milan, F Mainoldi, A Raimondi, C Fagioli, ... Nature immunology 14 (3), 298-305, 2013 | 437 | 2013 |
| A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells E Milan, T Perini, M Resnati, U Orfanelli, L Oliva, A Raimondi, P Cascio, ... Autophagy 11 (7), 1161-1178, 2015 | 101 | 2015 |
| Tight junction protein 1 modulates proteasome capacity and proteasome inhibitor sensitivity in multiple myeloma via EGFR/JAK1/STAT3 signaling XD Zhang, V Baladandayuthapani, H Lin, G Mulligan, B Li, DLW Esseltine, ... Cancer cell 29 (5), 639-652, 2016 | 97 | 2016 |
| Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors S Cenci, L Oliva, F Cerruti, E Milan, G Bianchi, M Raule, A Mezghrani, ... Journal of leukocyte biology 92 (5), 921-931, 2012 | 89 | 2012 |
| The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity L Oliva, U Orfanelli, M Resnati, A Raimondi, A Orsi, E Milan, G Palladini, ... Blood, The Journal of the American Society of Hematology 129 (15), 2132-2142, 2017 | 86 | 2017 |
| SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors E Milan, C Lazzari, S Anand, I Floriani, V Torri, C Sorlini, V Gregorc, ... Journal of proteomics 76, 91-101, 2012 | 76 | 2012 |
| Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells HW Auner, AM Moody, TH Ward, M Kraus, E Milan, P May, A Chaidos, ... PloS one 8 (9), e74415, 2013 | 66 | 2013 |
| Autophagy in plasma cell ontogeny and malignancy E Milan, M Fabbri, S Cenci Journal of Clinical Immunology 36, 18-24, 2016 | 39 | 2016 |
| The interaction of the tumor suppressor FAM46C with p62 and FNDC3 proteins integrates protein and secretory homeostasis C Fucci, M Resnati, E Riva, T Perini, E Ruggieri, U Orfanelli, F Paradiso, ... Cell reports 32 (12), 2020 | 32 | 2020 |
| Autophagy mediates epithelial cancer chemoresistance by reducing p62/SQSTM1 accumulation RA Battista, M Resnati, C Facchi, E Ruggieri, F Cremasco, F Paradiso, ... PLoS One 13 (8), e0201621, 2018 | 24 | 2018 |
| MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co‐opted from adaptive immunity E Benasciutti, E Mariani, L Oliva, M Scolari, E Perilli, E Barras, E Milan, ... Journal of Bone and Mineral Research 29 (2), 290-303, 2014 | 19 | 2014 |
| The autophagic process occurs in human bone metastasis and implicates molecular mechanisms differently affected by Rab5a in the early and late stages P Maroni, P Bendinelli, M Resnati, E Matteucci, E Milan, MA Desiderio International Journal of Molecular Sciences 17 (4), 443, 2016 | 18 | 2016 |
| The Immunity‐malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells T Perini, M Materozzi, E Milan The FEBS Journal 289 (15), 4383-4397, 2022 | 13 | 2022 |
| Single‐molecule real‐time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies P Cascino, A Nevone, M Piscitelli, C Scopelliti, M Girelli, G Mazzini, ... American Journal of Hematology 97 (11), E389-E392, 2022 | 9 | 2022 |
| Guidelines for the use and interpretation of assays for monitoring autophagy R Sanchez-Prieto, M Sandri, U Sankar, P Sansanwal, L Santambrogio, ... Autophagy 8 (4), 445544Klionsky, 2012 | 3 | 2012 |
| A novel proteomic signature of osteoclast differentiation unveils the deubiquitinase UCHL1 as a necessary osteoclastogenic driver M Materozzi, M Resnati, C Facchi, M Trudu, U Orfanelli, T Perini, ... Scientific Reports 14 (1), 7290, 2024 | | 2024 |
| TENT5C/FAM46C modulation in vivo reveals a trade-off between antibody secretion and tumor growth in multiple myeloma M Resnati, S Pennacchio, L Viviani, T Perini, M Materozzi, U Orfanelli, ... Haematologica, 2024 | | 2024 |
| P-363 Mitochondrial protease ClpP is a novel immunogenic vulnerability in multiple myeloma T Perini, P Zordan, R Del Pizzo, L Oliva, M Materozzi, M Samur, ... Clinical Lymphoma Myeloma and Leukemia 23, S239-S240, 2023 | | 2023 |
| P-204 Targeting TENT5C-associated regulation of antibody synthesis against multiple myeloma E Milan, M Resnati, S Pennacchio, L Viviani, T Perini, S Cenci Clinical Lymphoma Myeloma and Leukemia 23, S147-S148, 2023 | | 2023 |
